Rare disease drug development is challenging due to limited info on patient distribution, change in disease progression and relevant outcomes to define treatment benefits.
Expertise in mission-critical pricing, market access, and reimbursement.
Transforming recruitment through patient-centric trials and real-world, real-time data.
ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.
From recruitment of a single clinical professional to managing entire global functions.
FIRECREST: Digital solutions to increase efficiency in clinical trials by driving site performance.
Japan is the third-largest consumer of ethical drugs and the world’s third-largest economy; therefore, it is an important development centre for new medicines. However, there are various cultural and economic challenges in Japan that make it difficult to manage a fixed workforce against a variable portfolio of clinical research.
NICE published new guidance to give patients early access to innovative treatments by allowing greater flexibility considering a broader evidence base, making it easier for innovative and promising treatments to reach the patient incorporating the usage of real-world evidence.